Fitness7 months ago
Avelumab Plus Cisplatin-Based Chemotherapy Yields High EFS and OS Rates in MIUC
Neoadjuvant avelumab plus cisplatin-based chemotherapy in MIUC Event-free survival (EFS) and overall survival (OS) rates were high at 12- and 36-months among patients with muscle-invasive urothelial...
